key: cord-0862405-rz0kbuqm
authors: Fallet, Benedict; Kyburz, Diego; Walker, Ulrich A.
title: Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B‐cells due to treatment with rituximab
date: 2020-05-26
journal: Arthritis Rheumatol
DOI: 10.1002/art.41380
sha: 100c5214f7e05746fa9a6e4c3189cb747400a429
doc_id: 862405
cord_uid: rz0kbuqm

Over 4 million cases of Coronavirus disease 2019 (COVID‐19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been confirmed worldwide. Up to 20% of cases develop severe disease and the fatality rate are high.[1] Little is known however on the course of the infection in immunosuppressed patients. We therefore report the case of a patient with COVID‐19 under immunosuppression with rituximab. This 77‐year‐old woman was admitted to the hospital with a 5‐week history of unclear fever (up to 38.5°C), hypotension (80 mmHg systolic on self‐measurement), occasional mild shortness of breath and intermittent dry cough.

respiratory syndrome coronavirus 2 (SARS-CoV-2) have been confirmed worldwide. Up to 20% of cases develop severe disease and the fatality rate are high.[1] Little is known however on the course of the infection in immunosuppressed patients. We therefore report the case of a patient with COVID-19 under immunosuppression with rituximab. This 77-year-old woman was admitted to the hospital with a 5-week history of unclear fever (up to 38.5°C), hypotension (80 mmHg systolic on selfmeasurement), occasional mild shortness of breath and intermittent dry cough. Two years before she was diagnosed with granulomatosis and polyangiitis (GPA) presenting with otitis media, sinusitis and arthritis, for which she had received repeat courses of rituximab. She was on daily treatment with 5 mg of prednisone and 20 mg of weekly methotrexate. Further medication consisted of folic acid, calcium and vitamin D3, pantoprazole, rosuvastatin and zolendronate. Her main comorbidities were a Sjögren's syndrome, osteoporosis and hypercholesterolemia. Two weeks prior to admission, she had commenced a seven day course of amoxicillin-clavulanic acid for presumptive sinusitis which however had no effect on her fever. On admission, the clinical examination revealed no signs of active GPA. Her body temperature was 37.7°C, the respiratory rate 16/ min, the peripheral oxygen saturation 100%, the blood pressure 110/70 mmHg and the chest auscultation was normal. Eye, ear, nose and throat examinations were unremarkable, previously elevated proteinase-3 autoantibody titers had normalized. The B-cell compartment in the peripheral blood was completely depleted.

During her subsequent hospitalization, the patient continued to complain of fatigue and hypotension.

The fever and cough had settled. A chest computed tomography (CT) scan displayed new discrete bilateral ground glass opacifications in comparison to a CT carried out 2 years before, but no other remarkable lung pathology. Nasal swab testing by two independent real-time reverse-transcriptasepolymerase-chain-reactions (rRT-PCR) was positive for SARS-CoV-2 (viral load 149'000 copies/ml).

There was no SARS-CoV-2 viremia in the peripheral blood by rRT-PCR. The woman continued not to require any oxygen supply and stayed afebrile. On days 5 and 6 after admission, two consecutive nasopharyngeal swabs were negative for SARS-CoV-2 and the patient was discharged. SARS-CoV-2 serological testing detected no antiviral IgG (EDI TM Novel Coronavirus COVID-19 IgG ELISA, Epitope Diagnostics) up to 1 day after virus-clearance. Figure 1 antibodies correlated with disease severity in SARS patients. [4, 5] Although the magnitude and speed of antiviral antibody response was not associated with COVID-19 severity, [6] the complete lack of antiviral antibodies might have prevented severe disease in our patient. We can also not exclude that the additional treatment with methotrexate participated in mitigating immune-driven organ damage.

Interestingly, the patient successfully cleared the SARS-CoV-2 infection independent of specific antibody production. Although murine models point towards a critical role of antibodies, cellular

This article is protected by copyright. All rights reserved immunity also plays an important role in virus elimination and T-cell responses to some viral antigens have been shown to remain intact under rituximab exposure. [3, 6, 7] SARS-CoV-2 was confirmed in two independent PCRs, making a false positive result unlikely. An elevated body temperature was measured more than one month before SARS-CoV-2 detection. It remains unclear if the fever was due to COVID-19 during the entire period. The GPA showed no signs of activity and is therefore an unlikely cause of the fever. It is also unlikely that the alveolitis seen on CT represents rituximabinduced lung edema, given the 4-week time-lapse between rituximab infusion and imaging. Further studies are needed to determine the role of antiviral antibodies and immunosuppression in organ injury and viral clearance of COVID-19. 

Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection

Cellular immune response to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4 + T cells are important in control of SARS-CoV infection

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination

Figure 1: Graphic representation of symptoms presentation, progression of fever and CRP, diagnostic workup and treatments

Accepted Article